Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2022-01, Vol.24 (1), p.160-165
• Main Authors: Marfella, Raffaele, D'Onofrio, Nunzia, Sardu, Celestino, Scisciola, Lucia, Maggi, Paolo, Coppola, Nicola, Romano, Ciro, Messina, Vincenzo, Turriziani, Fabrizio, Siniscalchi, Mario, Maniscalco, Mauro, Boccalatte, Marco, Napolitano, Giovanni, Salemme, Luigi, Marfella, Ludovica Vittoria, Basile, Eugenio, Montemurro, Maria Vittoria, Papa, Carmela, Frascaria, Francesco, Papa, Antonio, Russo, Ferdinando, Tirino, Virginia, Papaccio, Gianpaolo, Galdiero, Marilena, Sasso, Ferdinando Carlo, Barbieri, Michelangela, Rizzo, Maria Rosaria, Balestrieri, Maria Luisa, Angelillo, Italo Francesco, Napoli, Claudio, Paolisso, Giuseppe
• Format: Article
• Language: English
• Subjects: Blood Glucose; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - immunology; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Glycated Hemoglobin A - analysis; Glycemic Control; Humans; Hyperglycemia; Immune system; Immunogenicity; Immunogenicity, Vaccine; Research Letter; Research Letters; Vaccine efficacy
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14547

Previous studies have shown that individuals with diabetes had a consistently lower immunological response to the hepatitis B vaccine,7 while less consistent results were noted for influenza and varicella-zoster vaccines.8 In this context, evaluating SARS-CoV-2 vaccine efficacy is critical to reducing the morbidity and mortality associated with COVID-19 in this vulnerable population. Testing vaccines that prevent infection with SARS-CoV-2 in T2D populations with poorly controlled glycaemia, therefore, is important because increased incidences of illness and death from COVID-19 have been associated with hyperglycaemia. Two doses of 30 μg BNT162b (Pfizer-BioNtech) elicited similar binding-antibody responses in people with or without T2D.9 However, there are no data on neutralizing antibodies and cell-mediated response to BNT162b vaccine in T2D patients, nor data on the immunological vaccine responses related to glycaemic control.10 The aim of the present study, therefore, was to evaluate cell-mediated response to the COVID-19 vaccine with regard to diabetic status and glycaemic control.